Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Review article on Triple Negative Breast Cancer, you can find online at Targeted Oncology, Evolving Paradigms in TNBC.

This is similar to the NEJM article about brain tumors, where there is an attempt to take existing knowledge about cancer pathology and morphology, and then to correlate with genetics. In other words, what mutations lead to what tumor types and how to individualize therapy.

They do not give percentages, just noting that TP53 plays a large role in these difficult to treat cancers, which are a smaller subset of all breast cancers(as you know). TNBC comprised of 18 subtypes (acc to article) with different genetic signatures.

When will all of this lead to better headlines for Kevetrin? Will it take 1 year, or 3, or 5? Currently my google news search for p53 and Cellceutix dredges up new law firm after new law firm looking into CTIX misrepresentations of its science, and little good news.

Looking forward to the day when we turn the corner and we start to hear about K in combo with X and Y and Z moving forward into all sorts of trials and all sorts of cancers.

For now, we are stuck in a dark dismal corner of the universe. PR's are about the final 3 patients being enrolled in phase 1. Does this mean we have to wait until this spring for phase 1 closure and release of data? Will it be pushed back to next ASCO? And when will we learn about the answer to the big question of whether Kevetrin actually works, now that we know it is safe? Hints from CEO have done nothing for the share price, that is for sure.